Uncategorized

BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial

BioCity Biopharma announced its endothelin receptor type A selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical trial of SC0062 in chronic kidney disease.

BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial Read More »

Olverembatinib Approved for Commercialization in Macau China

Ascentage Pharma announced that its novel BCR-ABL1 tyrosine kinase inhibitor, olverembatinib, has been approved by the Pharmaceutical Administration Bureau of the Macau SAR of the People’s Republic of China for the treatment of adult patients with tyrosine kinase inhibitors -resistant chronic-phase chronic myeloid leukemia or accelerated-phase CML harboring the T315I mutation.

Olverembatinib Approved for Commercialization in Macau China Read More »

Scroll to Top